Alteplase
- Generic Name
- Alteplase
- Brand Names
- Activase, Cathflo, Cathflo Activase
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 105857-23-6
- Unique Ingredient Identifier
- 1RXS4UE564
- Background
Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...
- Indication
Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...
- Associated Conditions
- Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis
- Associated Therapies
- -
Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
- Conditions
- Interventions
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 500
- Registration Number
- NCT00784134
- Locations
- 🇺🇸
Springfield Neurological and Spine Institute, Springfield, Missouri, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT00781378
- Locations
- 🇨🇳
The Second Affiliated Hospital of Hebei University, Shijiazhuang, Hebei, China
🇨🇳Shenyang Military Hospital, Shenyang, Liaoning, China
🇨🇳The Affiliated Hospital of Shenyang Medical University, Shenyang, Liaoning, China
Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas
- Conditions
- Interventions
- First Posted Date
- 2007-05-02
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Midwest Pulmonary and Critical Care
- Target Recruit Count
- 100
- Registration Number
- NCT00468104
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Safety and Effectiveness of tPA in Intra-abdominal Abscesses
- Conditions
- Interventions
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 35
- Registration Number
- NCT00417768
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 58
- Registration Number
- NCT00412867
- Locations
- 🇯🇵
Investigational site 01, Hokkaido, Japan
Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 20
- Registration Number
- NCT00284739
- Locations
- 🇺🇸
Kaiser Foundation Hospital, Honolulu, Hawaii, United States
Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 130
- Registration Number
- NCT00283088
- Locations
- 🇺🇸
Herman Memorial Hospital, Houston, Texas, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Saint Louis University Medical Center, St. Louis, Missouri, United States
Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 12
- Registration Number
- NCT00265005
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 270
- Registration Number
- NCT00148460
- Locations
- 🇰🇷
Dongsan Medical Center, Jung-Ku, Korea, Republic of
🇰🇷Chunnam University Hospital, Kwang-Ju, Korea, Republic of
🇨🇳Beijing University, Beijing, China
Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 103
- Registration Number
- NCT00147316
- Locations
- 🇯🇵
National Cardiovascular Center, Suita, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.